UroGen Pharma Ltd (URGN)
NASDAQ · Healthcare · Biotechnology
UroGen Pharma Ltd is a Healthcare company with a market capitalization of $2.38B.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $-0.47 | $-0.48 | +2.1% |
| Q4 2025 | March 2, 2026 | $-0.53 | $-0.48 | -9.9% |
| Q3 2025 | November 6, 2025 | $-0.69 | $-0.68 | -1.5% |
| Q2 2025 | August 7, 2025 | $-1.05 | $-0.82 | -28.1% |
| Q1 2025 | May 12, 2025 | $-0.92 | $-0.79 | -16.5% |
| Q4 2024 | March 10, 2025 | $-0.80 | $-0.72 | -11.1% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 5,689,384 | 11.34% | 6.9 | -8.5% |
| June 30, 2026 | 6,218,229 | 12.39% | 9.4 | -5.2% |
| June 15, 2026 | 6,557,146 | 13.07% | 9.9 | -5.3% |
| May 29, 2026 | 6,921,016 | 13.79% | 11.1 | +2.3% |
| May 15, 2026 | 6,764,905 | 13.48% | 5.8 | -6.5% |
| April 30, 2026 | 7,236,438 | 14.70% | 8.9 | -7.5% |
| April 15, 2026 | 7,826,923 | 15.90% | 11.2 | -6.3% |
| March 31, 2026 | 8,348,466 | 16.96% | 11.8 | -3.3% |
Other Biotechnology Stocks
Frequently Asked Questions
What is UroGen Pharma Ltd's market cap?
As of August 13, 2026, UroGen Pharma Ltd (URGN) has a market capitalization of $2.38B.
Does UroGen Pharma Ltd pay a dividend?
UroGen Pharma Ltd does not currently pay a dividend.
What sector is URGN in?
UroGen Pharma Ltd is in the Healthcare sector, specifically the Biotechnology industry.
What is UroGen Pharma Ltd's short interest?
As of the July 15, 2026 FINRA settlement, 5,689,384 URGN shares were sold short, or 11.34% of shares outstanding. Days to cover: 6.9. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was UroGen Pharma Ltd's revenue?
In its latest reported fiscal year (ending December 31, 2025), UroGen Pharma Ltd reported revenue of $109.79M and net income of -$153.49M.
Ask your own questions about URGN
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.